Autres langues ImmuCell Corporation

Actions

ICCC

US4525253062

Produits pharmaceutiques

Temps Différé Nasdaq Autres places de cotation 17:16:27 15/06/2026			Varia. 5j.	Varia. 1 janv.
9,540 ^USD	-1,45 %		-1,65 %	+55,12 %

15/05	Transcript : ImmuCell Corporation, Q1 2026 Earnings Call, May 15, 2026
14/05	ImmuCell Corporation publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Autres langues

14/05	ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
14/05	ImmuCell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026
08/05	ImmuCell, Norbrook enter settlement deed on May 8, 2026 - SEC filing
07/05	ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
22/04	ImmuCell : Corporate Presentation (Investor Relations April 2026 Final)
13/04	ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
13/04	ImmuCell Corporation Announces Board Changes
08/04	ImmuCell Q1 Sales Jump; Shares Rise After Hours
08/04	ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
08/04	Immucell Corporation Announces Preliminary, Unaudited Sales Results for the Firs Quarter of 2026
18/03	Immucell Corporation Announces Changes to Its Board, Effective April 1, 2026
18/03	ImmuCell : 03-18-26 – ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
18/03	ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
04/03	ImmuCell Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
04/03	ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
18/02	ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
09/02	Steven A. Rosgen and Bryan K. Gathagan Have Decided Not to Seek Re-Election as Directors of ImmuCell Corporation
08/01	ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
08/01	Immucell Corporation Announces Preliminary, Unaudited Sales Results for the Fourth Quarter and Full Year Ended December 31, 2025
07/01	ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
24/12	ImmuCell Pauses Investment in Cow Mastitis Drug After Receiving FDA Incomplete Letter
24/12	ImmuCell pauses investment in Re-Tain
24/12	ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
24/12	Immucell Announces Strategic Focus on First Defense® After Receiving an Fda Incomplete Letter for Re-Tain®
13/11	Animal health firm ImmuCell Q3 sales fall 8%, hurt by previous production interruptions